Your point #2 is why I have been wondering why many posters seem to think Gilead has the inside track on acquiring the B-CV license. Just because they have Rems... shouldn't mean squat IMO. Why would some other BP that realizes the whole anti-viral spectrum uses of B not fight just as hard to get the platform? Covid will be a nice foundation for B, but a spectrum-wide coronavirus would be a whole level more advantageous revenue base. Then throw in ALL enveloped and non-enveloped viruses (like the 20 now being tested by by DOD thru RBL)s and one is taken to another even higher level of revenues.
Gilead is no more than another suitor IMO. Deep pockets or very liberal partnership terms favoring IPIX are the keys to who wins the B lottery IMO.
(8)
(0)
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links